LIPO-102

DRUG5 trials

Sponsors

Neothetics, Inc

Conditions

Subcutaneous Abdominal AdipositySubcutaneous Adipose Tissue ReductionThyroid-Related Eye DiseaseWeight

Phase 1

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

CompletedNCT00918606

Neothetics, IncSubcutaneous Adipose Tissue Reduction

Start: 2009-02-28End: 2009-06-30Updated: 2015-03-24

Phase 2

Dose Ranging and Dose Frequency of LIPO-102

CompletedNCT00918814

Neothetics, IncSubcutaneous Adipose Tissue Reduction

Start: 2009-06-30End: 2010-02-28Updated: 2015-03-06

Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)

CompletedNCT00954057

Neothetics, IncThyroid-Related Eye Disease

Start: 2009-09-30End: 2011-06-30Updated: 2015-03-26

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

CompletedNCT01096979

Neothetics, IncSubcutaneous Abdominal Adiposity

Start: 2009-10-31End: 2010-03-31Updated: 2015-03-26

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

CompletedNCT01180465

Neothetics, IncWeight

Start: 2010-04-30End: 2010-09-30Updated: 2015-03-26